Genprex (GNPX) announced that The Israel Patent Office has granted Genprex a patent covering the use of Reqorsa Gene Therapy in combination with PD-1 antibodies for the treatment of cancer. This patent will expand on the previously granted patents for REQORSA in combination with PD-1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNPX:
- Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel
- Genprex Highlights Promising Preclinical Data for Diabetes Gene Therapy
- Genprex Expands Lung Cancer Gene Therapy Research Collaboration
- Genprex enters research agreement with UT MD Anderson
- Genprex announces presentations on Reqorsa Gene Therapy at 2026 AACR